Craig Lipset is Head of Clinical Innovation, Development Operations within Worldwide Research & Development at Pfizer. In this role, Craig works across units and stakeholders to define Pfizer’s vision for the future of clinical trials and enables the initiatives and investments to create that future. Most recently, Craig served as Venture Partner in Pfizer Venture Investments (Pfizer’s VC arm), where he focused on diversifying the company’s $50M annual budget for private investments in the areas of diagnostics and health technology. Craig was also Senior Director in Molecular Medicine, where he spearheaded initiatives driving innovation in clinical research and personalized medicines by drawing upon tools from health information technology, telemedicine, and eHealth.
Craig brings more than 15 years of leadership and innovation to the field of drug development. He previously served as Associate Vice President of Program Management at Adnexus Therapeutics (acquired by Bristol-Myers Squibb), and on the founding management team for Perceptive Informatics (now part of PAREXEL International). He has been listed among PharmaVOICE's
2010 most inspiring people in the life sciences and Pharmaceutical Executive’s
2011 Emerging Leaders. Outside Pfizer, Craig serves on the Board of Directors for the Foundation for Sarcoidosis Research.
Craig has enjoyed a variety of volunteer opportunities during his 13-year membership with DIA. In addition to Program Chair for DIA 2012, he is a member of the editorial board for the Drug Information Journal. Craig has supported a variety of programming needs for DIA, including track chair for the Annual Meeting program committee and vice-chair for the Portfolio Review Committee. In addition, Craig has served as chair of the Clinical Research SIAC and chair or speaker for many DIA programs, guest editor for a special issue of the Drug Information Journal, and on the DIA Election Task Force. He received the DIA Outstanding Service Award in 2010.